Stock Track | Avidity Biosciences Shares Tumble After Disappointing Q3 Earnings Miss

Stock Track

Nov 09, 2024

Shares of Avidity Biosciences, Inc. (RNA) plummeted by 5.48% on Wednesday after the biotech company reported lackluster third-quarter earnings results that fell short of Wall Street's expectations.

According to the company's earnings release, Avidity Biosciences reported an adjusted loss of $0.65 per share for the third quarter, wider than the average analyst estimate of a $0.71 loss per share. Revenue for the quarter came in at $2.34 million, significantly lower than the consensus forecast of $4.27 million.

The disappointing financial performance weighed heavily on investor sentiment, as Avidity Biosciences' shares faced selling pressure throughout the trading day. Analysts expressed concerns over the company's ability to meet its growth targets, citing the revenue shortfall as a potential red flag.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1135193388"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135193388\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135193388?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-09 05:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135193388","market":"hk","top_or_hot":-1,"title":"Stock Track | Avidity Biosciences Shares Tumble After Disappointing Q3 Earnings Miss","media":"Stock Track","content":"<p>Shares of Avidity Biosciences, Inc. (RNA) plummeted by 5.48% on Wednesday after the biotech company reported lackluster third-quarter earnings results that fell short of Wall Street's expectations.</p>\n\n<p>According to the company's earnings release, Avidity Biosciences reported an adjusted loss of $0.65 per share for the third quarter, wider than the average analyst estimate of a $0.71 loss per share. Revenue for the quarter came in at $2.34 million, significantly lower than the consensus forecast of $4.27 million.</p>\n\n<p>The disappointing financial performance weighed heavily on investor sentiment, as Avidity Biosciences' shares faced selling pressure throughout the trading day. Analysts expressed concerns over the company's ability to meet its growth targets, citing the revenue shortfall as a potential red flag.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Avidity Biosciences Shares Tumble After Disappointing Q3 Earnings Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Avidity Biosciences Shares Tumble After Disappointing Q3 Earnings Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-09 05:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Avidity Biosciences, Inc. (RNA) plummeted by 5.48% on Wednesday after the biotech company reported lackluster third-quarter earnings results that fell short of Wall Street's expectations.</p>\n\n<p>According to the company's earnings release, Avidity Biosciences reported an adjusted loss of $0.65 per share for the third quarter, wider than the average analyst estimate of a $0.71 loss per share. Revenue for the quarter came in at $2.34 million, significantly lower than the consensus forecast of $4.27 million.</p>\n\n<p>The disappointing financial performance weighed heavily on investor sentiment, as Avidity Biosciences' shares faced selling pressure throughout the trading day. Analysts expressed concerns over the company's ability to meet its growth targets, citing the revenue shortfall as a potential red flag.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RNA","symbol_name":"Avidity Biosciences, Inc.","start_time":0,"source_url":"","article_id":"1135193388","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135193388","pubTimestamp":1731100122,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Avidity Biosciences, Inc.  plummeted by 5.48% on Wednesday after the biotech company reported lackluster third-quarter earnings results that fell short of Wall Street's expectations.According to the company's earnings release, Avidity Biosciences reported an adjusted loss of $0.65 per share for the third quarter, wider than the average analyst estimate of a $0.71 loss per share. Revenue for the quarter came in at $2.34 million, significantly lower than the consensus forecast of $4.27 m","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RNA":"Avidity Biosciences, Inc."},"translate_title":"股票追踪Avidity Biosciences股价在第三季度盈利令人失望后暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":1},"content_text":"Shares of Avidity Biosciences, Inc. (RNA) plummeted by 5.48% on Wednesday after the biotech company reported lackluster third-quarter earnings results that fell short of Wall Street's expectations.\nAccording to the company's earnings release, Avidity Biosciences reported an adjusted loss of $0.65 per share for the third quarter, wider than the average analyst estimate of a $0.71 loss per share. Revenue for the quarter came in at $2.34 million, significantly lower than the consensus forecast of $4.27 million.\nThe disappointing financial performance weighed heavily on investor sentiment, as Avidity Biosciences' shares faced selling pressure throughout the trading day. Analysts expressed concerns over the company's ability to meet its growth targets, citing the revenue shortfall as a potential red flag.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}